Drug repurposing for COVID-19: Approaches, challenges and promising candidates

Traditional drug development and discovery has not kept pace with threats from emerging and re-emerging diseases such as Ebola virus, MERS-CoV and more recently, SARS-CoV-2. Among other reasons, the exorbitant costs, high attrition rate and extensive periods of time from research to market approval...

Descripción completa

Detalles Bibliográficos
Autores principales: Ng, Yan Ling, Salim, Cyrill Kafi, Chu, Justin Jang Hann
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Inc. 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8220862/
https://www.ncbi.nlm.nih.gov/pubmed/34174275
http://dx.doi.org/10.1016/j.pharmthera.2021.107930

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8220862/
https://www.ncbi.nlm.nih.gov/pubmed/34174275
http://dx.doi.org/10.1016/j.pharmthera.2021.107930

Ejemplares similares